ASCO Results: Oncologists Rank Genentech Number One

ASCO Results: Oncologists Rank Genentech Number One

SAN MATEO, Calif., June 10 -- When asked which company stood out at last week's ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail, Inc., a leader in oncology primary market research and influence network mapping solutions to the Global Life Sciences Industry.
In a brief on-line survey of 103 oncologists conducted soon after the close of the conference, AlphaDetail was able to gather some interesting feedback about oncologist perceptions of the meeting. The ASCO Annual Meeting attracts more than 30,000 attendees and is considered the premier educational and scientific event in the oncology community.


    --  60% of US oncologists attended the ASCO Annual Meeting.
    --  Oncologists rate Genentech #1 on overall image in oncology and cite it
        as the top company that stood out above the others at ASCO.
    --  Oncologists cite the following as the three most important pieces of
        data presented at ASCO:
        --  KRAS status predicts response to first-line cetuximab for
            metastatic colorectal cancer.
        --  Erbitux (cetuximab) + platinum-based chemotherapy extends overall
            survival in NSCLC vs. chemotherapy alone.
        --  Zometa (zoledronic acid) increases survival for premenopausal
            patients who received adjuvant endocrine therapy for early breast
            cancer.


To learn more about this study, please contact Bob Latshaw at [email protected] or (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our client's most challenging questions.

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.